BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

immatics biotechnologies GmbH 

Paul-Ehrlich-Strasse 15

Tuebingen    D-72076  Germany
Phone: 49-7071-565125-0 Fax: 49-7071-565125-99


SEARCH JOBS










 Company News
immatics biotechnologies GmbH Reels In €22 Million Series D 7/16/2014 6:22:49 AM
Promising Results In Phase 1 Trial Lead immatics biotechnologies GmbH To Continue Work On Vaccine (IMA950) For Glioblastoma 4/23/2014 12:53:51 PM
immatics biotechnologies GmbH, Roche (RHHBY) Ink Cancer Pact Worth Up To $1 Billion 11/13/2013 6:27:11 AM
immatics biotechnologies GmbH Snags $46 Million in Series D Financing Round 10/15/2013 7:58:29 AM
immatics biotechnologies GmbH to Present at CIMT Annual Meeting 2013 in Mainz, Germany 5/13/2013 10:16:12 AM
immatics biotechnologies GmbH' CSO to Present in Major Symposium at 2013 American Association for Cancer Research Annual Meeting in Washington D.C. 4/4/2013 9:55:34 AM
immatics biotechnologies GmbH's Co-Founder Professor Dr Hans-Georg Rammensee Awarded the Bayer AG (BAY.F) Hansen Family Award 2013 3/7/2013 10:59:44 AM
immatics biotechnologies GmbH Appoints Peter Chambre as Chairman 11/12/2012 1:10:08 PM
immatics biotechnologies GmbH's Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted U.S. Orphan Drug Designation by the FDA 11/8/2012 2:26:58 PM
immatics biotechnologies GmbH Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival 7/30/2012 10:38:37 AM
123